文献速递骨软组织肉瘤与黑色素瘤

西地尼布治疗腺泡状软组织肉瘤的CASPS双盲随机II期试验

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-05-31

CASPS是一项双盲、安慰剂对照、随机II期试验,纳入48例晚期腺泡状软组织肉瘤患者,按2:1随机接受西地尼布30mg每日一次或安慰剂治疗24周。

要点

  • 常见3级不良事件为高血压(19%)和腹泻(6%)。
  • 安慰剂组患者在第24周或进展后交叉至西地尼布组。

核心结论

  • 在腺泡状软组织肉瘤患者中,西地尼布较安慰剂显著缩小靶病灶,具有临床活性。

研究设计与样本

  • 双盲、安慰剂对照、随机II期试验,自英国7家、西班牙3家、澳大利亚2家医院招募48例患者。
  • 患者按2:1随机分配至西地尼布30mg口服每日一次(n=32)或安慰剂(n=16),治疗24周。
  • 主要终点为可评估人群中基线至第24周(或进展时)靶标记病灶直径总和的变化百分比。

主要发现

  • 西地尼布组最常见3级不良事件为高血压(6/31,19%)和腹泻(2/31,6%)。
  • 报告12例患者共15起严重不良反应,其中12起发生于开放标签西地尼布期间;1例安慰剂组患者在西地尼布开放标签开始后41天发生可能治疗相关死亡(颅内出血)。

临床怎么用

  • 对于化疗不敏感的转移性腺泡状软组织肉瘤,西地尼布可作为具有临床活性的治疗选择。

局限性

  • 样本量较小(共48例),主要终点基于可评估人群而非全部随机化人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. The Cediranib in Alveolar Soft Part Sarcoma (CASPS) study was designed to discriminate the effect of cediranib from the intrinsically indolent nature of ASPS. METHODS: In this double-blind, placebo-controlled, randomised, phase 2 trial, we recruited participants from 12 hospitals in the UK (n=7), Spain (n=3), and Australia (n=2). Patients were eligible if they were aged 16 years or older; metastatic ASPS that had progressed in the previous 6 months; had an ECOG performance status of 0-1; life expectancy of more than 12 weeks; and adequate bone marrow, hepatic, and renal function. Participants had to have no anti-cancer treatment within 4 weeks before trial entry, with exception of palliative radiotherapy. Participants were randomly assigned (2:1), with allocation by use of computer-generated random permuted blocks of six, to either cediranib (30 mg orally, once daily) or matching placebo tablets for 24 weeks. Treatment was supplied in number-coded bottles, masking participants and clinicians to assignment. Participants were unblinded at week 24 or sooner if they had progression defined by Response Evaluation Criteria in Solid Tumors (version 1.1); those on placebo crossed over to cediranib and all participants continued on treatment until progression or death. The primary endpoint was percentage change in sum of target marker lesion diameters between baseline and week 24 or progression if sooner, assessed in the evaluable population (all randomly assigned participants who had a scan at week 24 [or sooner if they progressed] with target marker lesions measured). Safety was assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01337401; the European Clinical Trials database, number EudraCT2010-021163-33; and the ISRCTN registry, number ISRCTN63733470 recruitment is complete and follow-up is ongoing. FINDINGS: Between July 15, 2011, and July 29, 2016, of 48 participants recruited, all were randomly assigned to cediranib (n=32) or placebo (n=16). 23 (48%) were female and the median age was 31 years (IQR 27-45). Median follow-up was 34·3 months (IQR 23·7-55·6) at the time of data cutoff for these analyses (April 11, 2018). Four participants in the cediranib group were not evaluable for the primary endpoint (one did not start treatment, and three did not have their scan at 24 weeks). Median percentage change in sum of target marker lesion diameters for the evaluable population was -8·3% (IQR -26·5 to 5·9) with cediranib versus 13·4% (IQR 1·1 to 21·3) with placebo (one-sided p=0·0010). The most common grade 3 adverse events on (blinded) cediranib were hypertension (six [19%] of 31) and diarrhoea (two [6%]). 15 serious adverse reactions in 12 patients were reported; 12 of these reactions occurred on open-label cediranib, and the most common symptoms were dehydration (n=2), vomiting (n=2), and proteinuria (n=2). One probable treatment-related death (intracranial haemorrhage) occurred 41 days after starting open-label cediranib in a patient who was assigned to placebo in the masked phase. INTERPRETATION: Given the high incidence of metastatic disease and poor long-term prognosis of ASPS, together with the lack of efficacy of conventional chemotherapy, our finding of significant clinical activity with cediranib in this disease is an important step towards the goal of long-term disease control for these young patients. Future clinical trials in ASPS are also likely to involve immune checkpoint inhibitors. FUNDING: Cancer Research UK and AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Judson I, Morden JP, Kilburn L, et al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol. 2019. PMID: 31160249. doi:10.1016/S1470-2045(19)30215-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。